Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ailsa Rose"'
Autor:
Julia V. Cockle, Anke Brüning-Richardson, Karen J. Scott, Jill Thompson, Timothy Kottke, Ewan Morrison, Azam Ismail, Angel M. Carcaboso, Ailsa Rose, Peter Selby, Joe Conner, Susan Picton, Susan Short, Richard Vile, Alan Melcher, Elizabeth Ilett
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 75-86 (2017)
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via immune-mediated mechanisms.
Externí odkaz:
https://doaj.org/article/6daa5830e2af4d63a0235f4c00e305f7
Autor:
Giorgia Cioccoloni, Alex Websdale, Liqian Ma, Erik R. Nelson, Madeline A. Henn, Priscilia Lianto, Joy J. Chen, Baek Kim, Laura M. Wastall, J. Bernadette Moore, James L. Thorne, Arindam Pramanik, Samantha A Hutchinson, Chrysa Soteriou, Hanne Roberg-Larsen, Ailsa Rose, Bethany Jill Williams, Thomas A. Hughes
Publikováno v:
Oncogene
Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db3c067f82a853ef98be6b1868b6deaa
http://hdl.handle.net/10852/92654
http://hdl.handle.net/10852/92654
Autor:
Laura M. Wastall, Priscilia Lianto, Thomas A. Hughes, Madeline A. Henn, Erik R. Nelson, Alex Websdale, Samantha A Hutchinson, Giorgia Cioccoloni, Chrysa Soteriou, Joy J. Chen, Hanne Roberg-Larsen, Liqian Ma, Bethany Jill Williams, Ailsa Rose, Baek Kim, James L. Thorne, J. Bernadette Moore
Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfde5a31acbb2190c142e4e5787d643a
https://doi.org/10.1101/2020.08.04.235697
https://doi.org/10.1101/2020.08.04.235697
Autor:
Priscilia Lianto, James L. Thorne, Bethany Jill Williams, Samantha A Hutchinson, Laura M. Wastall, Ailsa Rose, Alex Websdale, N. Sharma, Thomas A. Hughes, Hanne Roberg-Larsen
Publikováno v:
Proceedings of the Nutrition Society. 79
Autor:
Susan C Short, Elizabeth S. Appleton, Gemma Migneco, David Taggart, Simon Thomson, Gerard J. Nuovo, Lucy F. Stead, Sergio A. Quezada, Samantha J. Turnbull, Adel Samson, Philip van Hille, Richard G. Vile, Julia V. Cockle, D. Beirne, Fiona Collinson, Fiona Errington-Mais, Karen Scott, Peter Selby, Euan S. Polson, Kevin J. Harrington, Erica B. Wilson, Heiko Wurdak, Martin Fuller, Stephen Griffin, Jill Thompson, Timothy Kottke, Hardev Pandha, Gnanamurthy Sivakumar, Chris Twelves, Ailsa Rose, Christy Ralph, Andrew Furness, Elizabeth Ilett, Robert Corns, Emma West, D. Alan Anthoney, Matthew C. Coffey, Ryan K. Mathew, Alan Melcher
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined by tumor programmed death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4899fce1ad145ea879d424f0b5ba845
Autor:
Jill Thompson, Ewan E. Morrison, Joe Conner, Susan C Short, Peter Selby, Richard G. Vile, Julia V. Cockle, Elizabeth Ilett, Anke Brüning-Richardson, Timothy Kottke, Angel M. Carcaboso, Susan Picton, Karen Scott, Ailsa Rose, Azam Ismail, Alan Melcher
Publikováno v:
MOLECULAR THERAPY-ONCOLYTICS
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 75-86 (2017)
Molecular Therapy Oncolytics
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 75-86 (2017)
Molecular Therapy Oncolytics
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via immune-mediated mechanisms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea7e0d01d5f33a3e1e95f8e6b236fe88
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12425
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12425
Autor:
Susan C Short, Alan Melcher, Elizabeth Ilett, Ewan E. Morrison, Anke Brüning-Richardson, Karen Scott, Ailsa Rose, Jill Thompson, Susan Picton, Peter Selby, Azam Ismail, Julia V. Cockle, Richard G. Vile, Timothy Kottke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd30812a644e9b754898430fc5542ccc
https://europepmc.org/articles/PMC4903359/
https://europepmc.org/articles/PMC4903359/
Autor:
Christopher Parrish, Richard G. Vile, Michael J R Desborough, David T. Bowen, Fiona Errington-Mais, Hardev Pandha, Matthew C. Coffey, Karen Scott, Alan Melcher, Kathryn Hall, Ailsa Rose, Kevin J. Harrington
Publikováno v:
BioResearch Open Access
BioResearch Open Access, Vol 1, Iss 1, Pp 3-15 (2012)
BioResearch Open Access, Vol 1, Iss 1, Pp 3-15 (2012)
Reovirus is a naturally occurring oncolytic virus that has shown preclinical efficacy in the treatment of a wide range of tumor types and has now reached phase III testing in clinical trials. The anti-cancer activity of reovirus has been attributed t
Autor:
Ralph C. Anth, G. SivaKumar, Julia V. Cockle, Adel Jebar, G. Nuovo, Martin Fuller, R. Corns, Emma West, David Taggart, Elizabeth S. Appleton, Fiona Errington, Matthew C. Coffey, P. Van Hille, Ailsa Rose, Ryan K. Mathew, Karen Scott, Stephen Griffin, Gemma Migneco, Simon Thomson
INTRODUCTION: Oncolytic viruses preferentially replicate in cancer cells and kill them through direct cytotoxicity and/or immune mediated cell destruction. REOLYSIN® is a proprietary isolate of reovirus type 3 Dearing. In previous trials using intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bddeda69e86c87a10dc12b310a4e77
https://europepmc.org/articles/PMC4657649/
https://europepmc.org/articles/PMC4657649/
Autor:
Alison Merrick, Oliver Donnelly, Amer Aldouri, Hardev Pandha, Karen Scott, David Alan Anthoney, Emma West, Victoria A. Jennings, Peter Selby, Victoria Roulstone, Ruth Morgan, Matthew C. Coffey, Kevin J. Harrington, D. Beirne, Joan N. Kyula, Giles J. Toogood, Robin Prestwich, R. Adair, Gerard J. Nuovo, Martin Fuller, R. Dave, Richard G. Vile, S. Fraser, Alan Melcher, Ailsa Rose
Publikováno v:
Science translational medicine. 4(138)
Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune response, represent a promising approach to the treatment of cancer. However, how they evade the antiviral immune response and their selective delivery to, an